Pharmacy & Therapeutics/Drug Utilization Review Committee

April 13, 2026 – 2nd Quarterly P&T/DUR Meeting
8:00 AM-12:00 PM

Virtual:

Microsoft Teams Meeting:

Join: https://teams.microsoft.com/meet/27052306698947?p=I71oCHbFBlPiwnscGC

Meeting ID: 270 523 066 989 47

Passcode: eA6XJ3Zj

Dial in by phone

+1 505-312-4308,,769618770# United States, Albuquerque

(888) 506-1357,,769618770# United States (Toll-free)

Find a local number

Phone conference ID: 769 618 770#

Agenda Item	Leader
Welcome	K. Ryan
Approval of Agenda (Attachment A)	K. Ryan
Approval of Minutes from January 16, 2026, Meeting (Attachment B)	K. Ryan
State Updates • Turquoise Claims • Provider Enrollment • Need one Public P&T Member • P&T Chair	K. Ryan
Client Counts	Conduent

ProDUR	Conduent
RetroDUR	Conduent
Summary reports (Attachment C)	Conduent
Quarterly reports (Attachment D)	Conduent
Break – 9:00 Subject to change	K. Ryan
Closed Session PDL Class Review	K. Ryan
Open Session – 10:00 Subject to change	K. Ryan
HCA Administrative Updates • Launch Date 7/1/2026	Prime/ K. Ryan
Drug Class Review • Androgenic Agents • Antiemetic/Antivertigo Agents • Antimigraine Agents, Other • Antimigraine Agents, Triptans • Bone Resorption Suppression and Related Agents • COPD Agents • Glucocorticoids, Inhaled • Growth Hormones • Hypoglycemics, Insulin Related Agents • Hypoglycemics, SGLT2 • Immumodulators, Asthma • Immunomodulators, Atopic Dermatitis • Lipotropics, Other • Movement Disorders • Multiple Sclerosis Agents • Ophthalmic, Dry Eye Agents • PAH Agents, oral and Inhaled	Prime
Open Comments	K. Ryan
Adjournment	K. Ryan